agatolimod Report issue

Small molecule Experimental
AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW
  • Now
Agatolimod is a CpG Oligodeoxynucleotide which acts as a toll-like receptor 9 agonist. Agatolimod stimulates the immune system and has been tested for prevention and treatment of cancer, infectious diseases, allergies, and asthma.   Wikipedia

Chemistry

  • SMILES: Cc1cn([C@H]2C[C@H](OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3O)[C@@H](CO)O2)c(=O)[nH]c1=O
  • InChIKey: OKYYOKGIPDRZJA-CPSXWDTOSA-N
  • Mol. Mass: 7698.32
  • ALogP: Missing data
  • ChEMBL Molecules:
    agatolimod  
    agatolimod sodium  
More Chemistry

Pharmacology

Alternative names

agatolimod | agatolimod sodium | cp-7909 | cpg 2006 | cpg7907 | cpg 7907 | cpg-7907 | cpg7909 | cpg 7909 | cpg-7909 | cpg8916 | cpg 8916 | cpg-8916 | cpg8954 | cpg 8954 | cpg-8954 | pf03512676 | pf3512676 | pf 3512676 | pf-3512676 | promune

Organizations (26)

Research & Development (26)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (27)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (27)


 

Acne Vulgaris (Phase 1)

Breast Neoplasms (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Renal Cell (Phase 2)

Conjunctival Neoplasms (Phase 1)

Esophageal Neoplasms (Phase 1/Phase 2)

Healthy Volunteers (Phase 1)

Hepatitis B (Phase 1/Phase 2)

HIV Infections (Phase 1/Phase 2)

Influenza, Human (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1/Phase 2)

Lymphoma (Phase 2)

Lymphoma, B-Cell, Marginal Zone (Phase 1/Phase 2)

Lymphoma, Follicular (Phase 1/Phase 2)

Lymphoma, Large-Cell, Immunoblastic (Phase 1/Phase 2)

Lymphoma, Mantle-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Cutaneous (Phase 1/Phase 2)

Malaria (Phase 1/Phase 2)

Melanoma (Phase 2)

Mycosis Fungoides (Phase 1/Phase 2)

Neoplasms (Phase 1)

Prostatic Neoplasms (Phase 1)

Sepsis (Phase 1)

Vasculitis (Phase 1)

Waldenstrom Macroglobulinemia (Phase 1/Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 41
  • # of Trial Organizations: 26

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue